| Stereochemistry | ABSOLUTE |
| Molecular Formula | C47H80O18 |
| Molecular Weight | 933.1273 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O)C(C)(C)[C@]4([H])[C@H](C[C@@]23C)O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])OC[C@@H](O)[C@H](O)[C@H]6O)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=LLPWNQMSUYAGQI-OOSPGMBYSA-N
InChI=1S/C47H80O18/c1-21(2)10-9-13-47(8,65-41-37(59)34(56)32(54)26(18-48)62-41)22-11-15-45(6)30(22)23(50)16-28-44(5)14-12-29(52)43(3,4)39(44)25(17-46(28,45)7)61-42-38(35(57)33(55)27(19-49)63-42)64-40-36(58)31(53)24(51)20-60-40/h10,22-42,48-59H,9,11-20H2,1-8H3/t22-,23+,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,38+,39-,40-,41-,42+,44+,45+,46+,47-/m0/s1
Notoginsenoside R1 is a characteristic constituent of Radix notoginseng, a well known herbal medicine widely used in Asian countries for treating microcirculatory disturbance-related diseases, such as diabetic nephropathy, cardiovascular disease, cerebral vascular disease, and liver dysfunction. Notoginsenoside R1 has multiple pharmacologic activities, including cardioprotective, neuroprotective, anti-inflammatory, and anticancer effects. A study on the application of Notoginsenoside R1 in a rat model of diabetic nephropathy indicated that Notoginsenoside R1 ameliorated the glucose-induced impairment of podocyte adhesive capacity and subsequent podocyte depopulation, partly through the upregulation of α3β1 integrin via PI3K-Akt signaling pathway activation.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Notoginsenoside R1 was administrated orally at doses 5, 10 and 20 mg/kg•day to rats with diabetic nephropathy. Notoginsenoside R1was administered during 16 weeks.
Route of Administration:
Oral
SUBSTANCE RECORD
